IMMP Stock Analysis: Buy, Sell, or Hold?
IMMP - Immutep Limited American Depositary Shares
$0.45
0.03 (7.52%)
▲
5d:
+1.83%
30d:
+26.65%
90d:
+43.88%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Sep 04, 2026
Get Alerted When IMMP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IMMP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IMMP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IMMP is currently trading at $0.45, which is considered extended relative to its 30-day fair value range of $0.37 to $0.43.
Technical Outlook: Technically, IMMP is in a strong downtrend. The price is approaching resistance at $0.46. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.5% recently.
Market Sentiment: IMMP has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $1.50 (+233.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMMP is in a strong downtrend. The price is approaching resistance at $0.46. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.5% recently.
Market Sentiment: IMMP has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $1.50 (+233.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.37 -
$0.43
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.5%)
- BULLISH: Trading 233.0% below Wall St target ($1.50)
Trading Range Analysis
30-Day Trading Range
$0.37 -
$0.43
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.35
Resistance Level
$0.46
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.25
Wall Street Target
$1.50
(+233.0%)
Revenue Growth (YoY)
91.5%
Share & Embed Analysis
Last updated: July 14, 2026 6:14 AM ET
Data refreshes hourly during market hours. Next update: 7:14 AM
Data refreshes hourly during market hours. Next update: 7:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMMP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
